The article discusses the significant impact of kinase inhibitors (KIs) on cancer treatment, highlighting their potential in slowing cancer progression while minimizing chemotherapy's cytotoxic effects. It also emphasizes the pivotal role of physiologically-based pharmacokinetic (PBPK) modeling in understanding drug interactions, optimizing dosing, and expanding clinical trial participation, particularly in oncology drug development.